Current Seminars

03/12/2019 - 19:30 - Biopartnering Seminar Series- Group The Mightychondria Present

Abstract KYMRIAH (tisagenlecleucel) is a chimeric antigen receptor T-cell (CAR-T) therapy indicated for pediatric populations under 25 years old with B-cell acute lymphoblastic leukemia (ALL) and as a third-line treatment for adult populations with the most common form of relapsed or refractory non-Hodgkin lymphoma called diffuse large B-cell...

26/11/2019 - 18:30 - Biopartnering Seminar Series Presentations- Counterfeit Avastin by Team siRoNA

Abstract: Avastin (bevacizumab) is a life-extending and market-leading anti-VEGF therapeutic approved by Health Canada for a range of oncology indications. Batches of counterfeit Avastin (bevacizumab) containing no active ingredient were first detected in the United States supply chain and reported by the Food and Drug Administration (FDA) in...

19/11/2019 - 18:30 - Biopartnering Seminar Presentations- Janssen Inc. in Violation of the Competition Act

Abstract:  In 2018, the Canadian Competition Bureau launched an inquiry investigating allegations that Janssen Inc. engaged in activities that violate the Competition Act. This probe explored whether Janssen’s alleged behaviours prevented or inhibited biosimilars from competing with Janssen’s product Remicade in the...

12/11/2019 - 18:30 - Biopartnering Seminar Series- Zirre Tecch-The Rising Costs of Insulin: A Defense for Sanofi Aventis

Abstract: Over the last decade, the price of insulin within the United States (US) has skyrocketed, resulting in a high prevalence of rationing among diabetics whom the cost burden is placed on. In many cases, rationing has led to development of related severe adverse health conditions, or even death. Fed up with tolerating surging...

05/11/2019 - 06:30 - Biopartnering Seminar Series Presnations- Power RNAgers Group- Novartis Defending their Franchise, Lucentis (ranibizumab), Against Biosimilar Drugs

Abstract: This presentation focuses on strategies that will aid Novartis in defending their franchise, Lucentis (ranibizumab), against biosimilar drugs in Canada. Lucentis is an angiogenic monoclonal antibody fragment targeted to vascular endothelial growth factor, for the treatment of wet-age related macular degeneration (wAMD), diabetic...

Pages